668 related articles for article (PubMed ID: 18942660)
1. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
2. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
4. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
Green HJ; Pakenham KI; Headley BC; Gardiner RA
Psychooncology; 2002; 11(5):401-14. PubMed ID: 12228873
[TBL] [Abstract][Full Text] [Related]
5. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
7. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
Quella SK; Loprinzi CL; Sloan J; Novotny P; Perez EA; Burch PA; Antolak SJ; Pisansky TM
J Urol; 1999 Jul; 162(1):98-102. PubMed ID: 10379749
[TBL] [Abstract][Full Text] [Related]
8. Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.
Hanisch LJ; Gehrman PR
Aging Male; 2011 Dec; 14(4):243-8. PubMed ID: 21627561
[TBL] [Abstract][Full Text] [Related]
9. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
10. Hot flashes in prostate cancer: state of the science.
Engstrom CA
Am J Mens Health; 2008 Jun; 2(2):122-32. PubMed ID: 19477776
[TBL] [Abstract][Full Text] [Related]
11. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
[TBL] [Abstract][Full Text] [Related]
12. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
15. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Freedland SJ; Eastham J; Shore N
Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
[TBL] [Abstract][Full Text] [Related]
17. Managing hot flashes in men being treated for prostate cancer.
Baum NH; Torti DC
Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
[TBL] [Abstract][Full Text] [Related]
19. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Cury FL; Souhami L; Rajan R; Tanguay S; Gagnon B; Duclos M; Shenouda G; Faria SL; David M; Freeman CR
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):842-8. PubMed ID: 16289909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]